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Abstract 
Hepatic epithelioid hemangioendothelioma
(HEH) is a rare disease of unknown etiology
for which a standard systemic treatment has
not been established. The common expression
of vascular endothelial growth factor (VEGF)
and its receptor in HEH provide a rationale for
the reported use of antiangiogenic drugs,
including bevacizumab, lenalidomide and
thalidomide. We report a case of a young male
patient with HEH who was treated with
sorafenib for almost 2 years. Sorafenib was
used instead of other VEGF inhibitors due to
its convenient oral route, its dual antiangio-
genic and antiproliferative activity, and its
favorable safety profile. Sorafenib therapy
resulted in durable stabilization with progres-
sive calcification of liver tumors and minor but
stable response of lung lesions.
Introduction
Epithelioid hemangioendothelioma (EH) is
a rare malignant vascular soft tissue sarcoma
of unknown etiology. Liver is the organ which
is most frequently involved by primary EH,
although this tumor can develop from any vis-
ceral or soft tissue site. For hepatic epithelioid
hemangioendothelioma (HEH), a comprehen-
sive review of literature from 1984 to 2005
includes 402 published cases and shows a light
female predominance (3/2) as well as a medi-
an age of 42 years with a very wide range (3-
86).1 Also, this review showed that the most
frequent first-symptom was right upper quad-
rant pain (49%); the tumor frequently involved
both hepatic lobes (81%) and than, although
63% of the patients were non-metastatic when
extrahepatic lesions were present, lung was
the most frequent site of metastases (13% of
the patients with metastases).
EH is characterized by an often unpre-
dictable clinical course. Whereas some
patients present a rapidly progressive disease,
others may remain stable for several years.
Liver primary location carries a poor prognosis
among the primary sites of EH origin.
However, 5-year overall survival of HEH
patients after standard primary radical treat-
ment is 55%, and thereby, it is one of the liver
malignancies that is associated with a better
prognosis among all liver malignancies.2
Moreover, HEH patients undergoing liver
transplantation have a 10-year survival rate
above 70%.3 Standard treatment options for
liver-limited HEH include liver resection, liver
transplantation or transcatheter arterial
chemoembolization.1,4 Radioembolization is a
promising but yet investigational option for
these patients.5 A standard systemic treatment
has not been established for advanced HEH.
Previous literature highlights single case
reports of patients treated with several anti-
cancer agents, but case series or phase II clin-
ical trials are lacking. Some of these case
reports showed successful treatment with
interferon, an agent with immunomodulatory
and antiangiogenic activity.6-8 Besides, the
expression of both vascular endothelial growth
factor (VEGF) or its receptor (VEGFR) VEGF in
HEH provide a rationale for the use of antian-
giogenic drugs.9 Among the more than 200
studies published in English over the last 5
years about EH, those reporting the results of
new systemic agents only consider antiangio-
genic agents such as bevacizumab, lenalido-
mide and thalidomide. Therefore, antiangio-
genic therapy could be an option to treat EH
and HEH. We are reporting herein a case of
HEH successfully treated with the antiangio-
genic agent sorafenib. 
Case Report
A 22 years old male patient, with a previous
history of type 1 diabetes, presented with pain
in the left side of the chest for about 2 months
and a slightly altered performance status
(Eastern Cooperative Oncology Group score 1).
General examination disclosed nothing but a
small hepatomegaly and the results from blood
tests including liver function tests within nor-
mal limits. A chest and abdominal computed
tomography (CT) scan showed multiple bilat-
eral pulmonary nodules and at least 6 hypo-
dense liver lesions suggestive of metastases,
one of them in close contact with the right
branch of the portal vein. No bone metastases
were detected by bone scintigraphy. Serum
tumor markers including carcinoembryonic
antigen and alpha-fetoprotein were normal. An
ultrasound-guided percutaneous liver biopsy
showed that the liver parenchyma was mas-
sively replaced by a fibrotic tissue containing
poligonal tumor cells with round nuclei and a
relatively scarce cytoplasm containing vacuo-
lae. In the boundaries of the tumor areas
tumor cells showed a sinusoidal growth pat-
tern. Immunohistochemically, tumor cells had
a positive staining by CD-34, (cytoplasmatic
diffuse 100%), CD-31 (cytoplasmatic diffuse
100%), keratine AE3/AE1 (cytoplasmatic focal),
VEGF (intense immunoreactivity, in both
membrane and cytoplasm in almost 100% of
cells) and were negative by c-erb-B2, EGFR and
c-kit. The final pathologic diagnosis was liver
epithelioid hemangioendothelioma. 
Treatment with sorafenib (Nexavar™ 200
mg tablets), 2 tablets/12 hours (total 800
mg/day) was started in October 2009. Two
weeks later, the patient required temporary
discontinuation of the treatment due to grade
3 mucocutaneous toxicity (a combination of
mucositis, multiform erythema and hand-foot
syndrome). After toxicity was resolved, treat-
ment was reinitiated at a reduced dose of 200
mg bid which resulted in partial improvement
of side effects. Three months later, in January
2010, chest pain (the primary symptom) had
subsided and toxicity consisted of grade 1 mul-
tiform erythema, grade 2 hand-foot-syndrome,
grade 1 alopecia and grade 1 mucositis.
Sorafenib dose was further reduced and since
January 2011 a final dose of 200 mg every 36
hours resulted in no mucositis or multiform
erythema, and grade 1 hand-foot syndrome. 
As shown in Figures 1 and 2, evaluation of
tumor response by means of serial CT scans
showed a favorable response with a decrease
in the size of the lung metastases, disappear-
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ance of the left pleural thickening, and a pro-
gressive calcification of the liver metastases
that nevertheless experienced no major
changes in size. Altogether, using Response
Evaluation Criteria In Solid Tumors criteria v.
1.0,10 tumor response consisted in a prolonged
stabilization. As it can also be observed, after a
distinct lung infiltrate appeared in June 2011,
a bronchoalveolar lavage disclosed
Mycobacterium tuberculosis and the patient is
currently receiving tuberculostatic agents. 
Discussion
The present case report describes a typical
case of HEH. The symptoms (abdominal pain,
hepatomegaly), the site of metastases (lung)
and the bilobar liver involvement are all char-
acteristic of the initial presentation of this
tumor. A small number of single case reports of
HEH patients treated with cytotoxic
chemotherapy have been published. The most
frequently used agent is doxorubicin,11,12 or its
liposomal formulation.13,14 However, the results
have been far from ideal and HEH is consid-
ered a poorly chemosensitive tumor. In the last
years antiangiogenic agents that block the
VEGF or its receptor, VEGFR, have emerged as
anticancer agents. The Raf/MEK/ERK signaling
pathway is a key step in both proliferation and
angiogenesis. Sorafenib is an inhibitor of the
tyrosine-kinase (TK) associated to this signal-
ing pathway. In addition, sorafenib strongly
inhibits several TK associated with molecules
involved in the angiogenesis process, such as
VEGFR-2 and 3 and platelet derived growth fac-
tor-β.15 Sorafenib is currently a standard treat-
ment for the treatment of both advanced hepa-
tocellular carcinoma and advanced renal-cell
carcinoma.16,17 A phase I clinical trial of
sorafenib in patients with solid tumors showed
promising efficacy in patients with advanced
sarcomas.18 Furthermore, a phase II clinical
trial, enrolled 145 patients and showed a
response rate of 14% in angiosarcoma patients
but minimal activity against other sarcomas.19
A difference in clinical benefit between vascu-
lar and nonvascular sarcomas (liposarcoma
and leyomiosarcoma) was also observed in
another clinical trial which enrolled 51
patients.20 Vascular-sarcoma patients in this
trial achieved a higher rate of disease stabi-
lization and a longer progression-free survival
when compared with the group of nonvascular-
sarcoma patients. 
Vascular sarcomas are inherently a possible
target for antiangiogenic therapy. Emamaulee
et al. investigated the expression of VEGF by
means of immunohistochemical assessment
in a small study. They found positivity in 6 out
of 6 samples of HEH.21 This result, together
with the efficacy shown by interferon and
other antiangiogenic agents,6-8 such as thalido-
mide and lenalidomide,22-24 in patients with
advanced HEH supports the role of angiogenic
pathways as possible targets in patients with
HEH. Thus, the initiation of the treatment with
the antiangiogenic agent sorafenib was sup-
ported by this background. The reason for
choosing sorafenib instead of other VEGF
inhibitors was mainly the convenience of the
oral route, its dual antitumor activity (antian-
giogenic and antiproliferative), and the differ-
ent safety profile. The lower incidence of
fatigue and hypertension of sorafenib com-
pared to sunitinib (37% vs. 74% and 17% vs.
28%, respectively, as reported in the package
inserts) were judged important due to the age
of the patient and the coexistence of diabetes.
Its better tolerance and stronger antiangio-
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Figure 1. Computed tomography scan showing the evolution of liver metastases at differ-
ent times.
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genic activity moved us to prefer sorafenib to
interferon.
The response achieved in our case was a
prolonged stabilization associated with signif-
icant intratumoral changes. The response was
dissociated, with minor tumor size reduction
being observed in the lungs as compared with
liver, where progressive calcification, instead
of tumor shrinkage, was the main sign of
response. Calcification and other changes in
tumor density without clear tumor shrinkage
are considered as highly suggestive of tumor
response, especially after the introduction of
the newest antineoplastic molecular-targeted
therapies.25 Sorafenib may have the advantage,
over other previous antiangiogenic agents, of
its dual antitumor activity (antiangiogenic and
antiproliferative). HEH is a rare tumor for
which clinical trials involving a relevant num-
ber of patients are not feasible. In fact, a major
objective response was not observed in our
case. Nevertheless, we believe that this case
provides encouraging evidence of the potential
benefit of continued sorafenib treatment in
patients with HEH.
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